Candida auris can persist for long periods on hospital surfaces and on the skin. C. auris has the ability to form drug-resistant biofilms, which can substantially impact on patient outcome. In comparison to Candida albicans, C. auris has a lower capacity to form biofilms in in vitro models and a higher capacity when tested on animal skin models. Intraspecies variation is shown to exist, with some clinical isolates having greater biofilm capabilities than others. There is a need for models that closely mimic the real niches where infection occurs on human patients. This protocol describes, in detail, a human skin model to study C. auris biofilm formation using catheterized and non-catheterized skin.
|Number of pages||9|
|Journal||Methods in molecular biology (Clifton, N.J.)|
|Publication status||Published - 9 Jun 2022|
- Antifungal Agents/pharmacology
- Candida albicans
- Candida auris
- Candidiasis/drug therapy